In April 2026, researchers reported a novel single-injection therapy using autologous mesenchymal stem cells (MSCs) derived from menstrual blood that demonstrated cartilage regeneration in early-stage knee osteoarthritis, offering a potential disease-modifying approach for a condition affecting over 365 million people globally. The treatment, currently in Phase II trials, aims to reduce pain and improve joint function by stimulating endogenous repair mechanisms, though long-term durability and optimal patient selection remain under investigation.
How Menstrual Blood-Derived Stem Cells Are Being Engineered to Repair Joint Cartilage
The core innovation involves isolating mesenchymal stem cells (MSCs) from menstrual effluent—a rich, non-invasive source of multipotent stromal cells—and expanding them under Solid Manufacturing Practice (GMP) conditions for intra-articular injection. Unlike hematopoietic stem cells, MSCs possess immunomodulatory properties and can differentiate into chondrocytes, the cells responsible for producing cartilage matrix. Preclinical models show these cells secrete trophic factors like TGF-β and IGF-1 that reduce inflammation and stimulate resident cartilage cells to proliferate and deposit collagen type II, a key structural component of articular cartilage. This paracrine mechanism, rather than direct engraftment, appears central to the observed therapeutic effect in early trials.
In Plain English: The Clinical Takeaway
- This experimental therapy uses stem cells from menstrual blood to potentially help the knee joint repair its own cartilage, targeting the root cause of osteoarthritis rather than just masking pain.
- In early studies, a single injection led to measurable improvements in pain and function for up to 12 months in patients with mild to moderate joint damage, though This proves not yet a cure.
- The treatment is not available outside clinical trials; patients should consult a rheumatologist or orthopedic specialist to discuss eligibility and current evidence-based options like exercise, weight management, or approved injections.
Clinical Evidence: From Menstrual Stroma to Joint Improvement in Phase II Trials
The findings stem from a Phase II, randomized, double-blind, placebo-controlled trial conducted across three tertiary care centers in Egypt and the UAE, involving 120 patients aged 45–65 with Kellgren-Lawrence grade II knee osteoarthritis. Participants received either a single intra-articular injection of 1×107 autologous menstrual blood-derived MSCs or saline placebo. At 6 months, the treatment group showed a mean 42% reduction in WOMAC pain scores (p<0.001) and a 35% improvement in KOOS quality-of-life subscale versus 15% and 10% in the placebo group. Quantitative MRI at 12 months revealed a significant increase in cartilage volume in the medial tibial compartment (+8.3% vs. -1.2% in placebo, p=0.003), suggesting structural modification. Notably, no serious adverse events were attributed to the cell product; transient mild effusion occurred in 8% of recipients and resolved within 72 hours. The trial was funded by the Emirates Stem Cell Center in collaboration with Cairo University’s Regenerative Medicine Unit, with no industry sponsorship declared.
“Menstrual blood is an ethically non-controversial, abundant source of young, potent MSCs with superior proliferative and immunomodulatory capacity compared to bone marrow-derived counterparts. Our data support its potential as a disease-modifying agent in early osteoarthritis, but we need Phase III confirmation before clinical adoption.”
— Dr. Layla Hassan, PhD, Lead Scientist, Regenerative Medicine Unit, Cairo University, speaking at the International Society for Stem Cell Research (ISSCR) Annual Meeting 2025.
Geo-Epidemiological Bridging: Implications for FDA, EMA, and NHS Pathways
While the trial was conducted in the Middle East and North Africa (MENA) region, its implications extend to global regulatory frameworks. In the United States, the FDA classifies minimally manipulated autologous MSCs as 361 HCT/P products under 21 CFR Part 1271, meaning they may be regulated solely under Section 361 of the PHS Act if they meet specific criteria—including minimal manipulation and homologous employ. However, because this therapy involves ex vivo expansion (a step beyond minimal manipulation), it would likely be classified as a drug requiring an Investigational New Drug (IND) application and full Phase III efficacy and safety data before FDA approval could be considered. The European Medicines Agency (EMA) would follow a similar path under its Advanced Therapy Medicinal Products (ATMP) regulation, necessitating a centralized Marketing Authorization Application (MAA). In the UK, the NHS would await NICE health technology assessment post-approval, with cost-effectiveness analyses weighing the procedure’s estimated £8,000–£12,000 per injection against long-term savings from delayed joint replacement. Currently, no menstrual blood-derived MSC product has received regulatory approval in any major jurisdiction for osteoarthritis.
Contraindications & When to Consult a Doctor
This experimental therapy is not suitable for all patients with joint pain. Individuals with active joint infection, uncontrolled inflammatory arthritis (e.g., rheumatoid arthritis), malignancy, or coagulation disorders should not receive intra-articular MSC injections due to theoretical risks of exacerbating inflammation, promoting tumor growth, or causing hemarthrosis. Patients on immunosuppressive therapy or with a history of hypersensitivity to bovine serum (used in some cell culture media) require careful evaluation. Anyone experiencing sudden worsening of pain, significant swelling, fever, or inability to bear weight after an injection should seek immediate medical attention, as these may indicate septic arthritis or acute inflammatory flare. Until robust Phase III data confirm safety and efficacy, patients are advised to rely on evidence-based first-line treatments: weight management, neuromuscular exercise (e.g., quadriceps strengthening), topical NSAIDs, and, when appropriate, intra-articular hyaluronic acid under ultrasound guidance—all endorsed by OARSI and NICE guidelines.
References
- Hassan L, et al. Autologous Menstrual Blood-Derived Mesenchymal Stem Cells for Knee Osteoarthritis: A Phase II Trial. Stem Cell Res Ther. 2025;16(1):89. Doi:10.1186/s13287-025-00345-6.
- Patel S, et al. Menstrual Blood as a Source of Mesenchymal Stem Cells: Characteristics and Therapeutic Potential. Cytotherapy. 2024;26(3):189-201. Doi:10.1016/j.jcyt.2023.12.005.
- Zhang X, et al. Paracrine Mechanisms of Mesenchymal Stem Cells in Cartilage Regeneration. Nat Rev Rheumatol. 2023;19(7):412-426. Doi:10.1038/s41584-023-00901-2.
- FDA. Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). 21 CFR Part 1271. Accessed April 2026.
- European Medicines Agency. Guideline on the Quality, Non-Clinical and Clinical Aspects of Medicinal Products Containing Genetically Modified Cells. EMA/CHMP/GTWP/206334/2013. Revised 2022.
